Clinical trials: Hepatic Cirrhosis
Cirrhosis
Intravenous Ciprofloxacin Versus Intravenous Ceftriaxone: Spontaneous Bacterial Peritonitis in Cirrhosis of Liver
Spontaneous bacterial peritonitis (SBP) is one of the leading causes of morbidity and mortality in patients with cirrhosis. Spontaneous bacterial peritonitis (SBP) is a common bacterial infection in patients with cirrhosis and…
- Trial name
- NCT07552870
- Testing
- intravenous ciprofloxacin, intravenous ceftriaxone
- Where
- Pakistan
- Volunteers
- 310 people
- Sponsor
- Shahida Islam Medical Complex
Primary Biliary Cirrhosis
Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation for Children Suffering From Biliary Atresia
Biliary atresia (BA) is the most frequent cause of chronic cholestasis in neonates, accounting for at least 50% of pediatric liver transplantation. BA incidence is estimated to range from 1:5000 to 1:19000 live births.
- Trial name
- UCMSCBA (NCT04522869)
- Testing
- Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation
- Where
- 2 sites in Vietnam
- Volunteers
- 20 people
- Sponsor
- Vinmec Research Institute of Stem Cell and Gene Technology
Chronic Hepatitis C, Fibrosis
Combination Drug Therapy for Patients With Hepatitis C
Hepatitis C is a major cause of liver disease in the United States and leads to cirrhosis of the liver in approximately one-third of patients some of whom will ultimately suffer from liver failure or liver cancer.
- Conditions
- Chronic Hepatitis C, Fibrosis, Hemolytic Anemia
- Trial name
- NCT00001729
- Testing
- Ribavirin
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Liver Cirrhosis
Renal Function Determination in Patients With Liver Cirrhosis
We have several ways to appropriately determine renal function in healthy patients and in several diseases, in cirrhotic population we dont have a precise tool that has sufficient precision that reflects glomerular function…
- Trial name
- NCT02047240
- Where
- Mexico
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Primary Biliary Cholangitis (PBC)
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) and cirrhosis (scarring of the liver). PBC is a slowly progressive disease, characterised by damage to the bile ducts in the liver, leading to a…
- Trial name
- ELFIDENCE (NCT06016842)
- Testing
- Elafibranor
- Where
- 198 sites in United States, Argentina and 26 more
- Volunteers
- 276 people
- Sponsor
- Ipsen
Liver Fibrosis, Fatty Liver
Comparison of iLivTouch and FibroScan for the Assessment of Liver Fibrosis and Steatosis in Adult Patients in the US
This is a multi-center, cross-sectional, and prospective study that will recruit patients from multiple hospitals or outpatient clinics in the USA to the comparison of iLivTouch and FibroScan for the assessment of liver fibrosis…
- Trial name
- NCT06051669
- Testing
- iLivTouch, FibroScan
- Where
- 4 sites in United States
- Volunteers
- 418 people
- Sponsor
- New Discovery LLC
Hepatitis B, Liver Fibrosis
Optimized Treatment of Peginterferon Alfa 2a/2b in Treatment Experienced Patients With HBV Related Liver Fibrosis
Compared to nucleoside/nucleotide analogues, peginterferon alfa 2a/2b may has more therapeutic efficacy in hepatitis B surface antigen or e antigen seroconversion and anti-tumor occurrence in chronic hepatitis b patients.
- Trial name
- HBV (NCT03920605)
- Testing
- Tenofovir Disoproxil Fumarate, Peginterferon Alfa-2a, Peginterferon Alfa-2b
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Cholestasis
Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Subjects
In participants with inadequate response/intolerance to ursodeoxycholic acid (UDCA) taking obeticholic acid (OCA) who experience pruritus (due to primary biliary cholangitis [PBC], OCA, or both) the addition of linerixibat to OCA…
- Trial name
- NCT04053023
- Testing
- GSK2330672 (linerixibat), Obeticholic acid
- Where
- United Kingdom
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Liver Cirrhosis
Coagulation in Cirrhosis
Out of fear of bleeding, liver cirrhosis patients are often treated prophylactically with blood and coagulation products before minor interventions.
- Trial name
- COUCH (NCT05667805)
- Testing
- Platelet Concentrate, Prothrombin Complex Concentrate, Restricitve Use
- Where
- Austria
- Volunteers
- 400 people
- Sponsor
- Medical University of Vienna
Liver Cirrhosis, Portal Hypertension
Rifaximin and Propranolol Combination Therapy Versus Propranolol Monotherapy in Cirrhotic Patients
To reduce portal pressure, the only recommended medication is nonselective beta blocker(NSBB). However, NSBB has some limitation to apply clinically because of poor response rate and compliance.
- Trial name
- RECOVER (NCT01897051)
- Testing
- Rifaximin + propranolol
- Where
- 2 sites in South Korea
- Volunteers
- 140 people
- Sponsor
- Yonsei University
Portal Hypertension, Chronic Liver Disease
Non-invasive Diagnosis of Portal Hypertension With Acoustic Radiation Force Impulse (ARFI)
The aim of this diagnostic study is to evaluate the efficacy of ARFI imaging (a specific type of ultrasound) in assessing the pressure of the portal vein (the major vein passing through the liver) and the amount of liver fibrosis…
- Trial name
- NCT01644656
- Testing
- ARFI ultrasound
- Where
- 2 sites in United States
- Volunteers
- 500 people
- Sponsor
- VA Connecticut Healthcare System
Cirrhosis, Hepatic Encephalopathy
Factors Associated With End Stage Liver Disease
100 ambulatory cirrhotic patients attending a liver transplant clinic will undergo a comprehensive clinical evaluation for severity of liver disease, anemia, depression, and fatigue.
- Conditions
- Cirrhosis, Hepatic Encephalopathy, Fatigue, Depression
- Trial name
- NCT01846819
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Patients Without a Medical History of Thrombosis or Hemorrhage, Hemophilic Patient
Evaluation of the Inter-center Variability of the Measurement of Thrombin Generation by the ST Genesia System
The thrombin generation test is a global test for the study of coagulation that allows the fine study of the balance between procoagulant and anticoagulant factors.
- Conditions
- Patients Without a Medical History of Thrombosis or Hemorrhage, Hemophilic Patient, Patient With FV Leiden Mutation, Patient With Cirrhosis
- Trial name
- EVIGE (NCT05422157)
- Where
- France
- Volunteers
- 71 people
- Sponsor
- University Hospital, Clermont-Ferrand
Liver Fibrosis, Hepatic Cirrhosis
Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis
The purpose of this study is to evaluate the safety, tolerability, and pharmacodynamic effects of AZD2389 in adult participants with steatotic liver disease (SLD) and advanced fibrosis.
- Trial name
- BRAVO (NCT07610837)
- Testing
- AZD2389
- Where
- 21 sites in United States, Puerto Rico
- Volunteers
- 104 people
- Sponsor
- AstraZeneca
Liver Transplantation, Auxiliary Liver Transplantation
Rejection After Auxiliary Partial Orthotopic Liver Transplantation: An Exploratory Comparison by Native-Liver Cirrhosis Status
This retrospective single-center cohort study aims to investigate the association between native-liver cirrhosis status and post-transplant outcomes in recipients undergoing auxiliary partial orthotopic liver transplantation…
- Trial name
- NCT07275008
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Zhi-Jun Zhu
Alcoholic Liver Cirrhosis
The Effectiveness and Safety for Mesenchymal Stem Cell for Alcoholic Liver Cirrhosis
Background \& Aim: Bone marrow derived mesenchymal stem cells (BM-MSCs) have capacity to differentiate into hepatocytes and anti-fibrotic effect in the experimental model.
- Trial name
- NCT01741090
- Testing
- mesenchymal stem cell injection
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Yonsei University
Hepatitis C, Liver Cirrhosis
Assessment of Patients With Hepatitis C Virus Related Liver Cirrhosis After Sustained Response to Direct Acting Anti Viral Drugs.
Hepatitis C Virus (HCV) infection is a major global health challenge; it is estimated that more than 80 million people are chronically infected worldwide, with 3-4 million new infections and 350,000 deaths occurring each year…
- Trial name
- NCT03241823
- Testing
- Abdominal ultrasound ., Model for End-Stage Liver Disease, Fibro Scan.
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Assiut University
Liver Cirrhosis
Care Algorithm and Clinic Decision System on Hepatic Rehabilitation in Patients With Liver Cirrhosis
Liver cirrhosis is an important public health problem that causes morbidity and mortality. In order to provide hepatic rehabilitation of patients with liver cirrhosis, interventions that provide active care practices by patients…
- Trial name
- ReLiver-NApp (NCT06995196)
- Testing
- ReLiver-N App
- Where
- Turkey (Türkiye)
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Akdeniz University
HCC, Liver Cirrhosis
SALT for Liver Cirrhosis With HCC
HCC is the third leading cause of cancer deaths worldwide. Although surgical treatment may be effective in patients with HCC, the five-year survival rate is only 50-70%.
- Trial name
- NCT06069947
- Testing
- sequential adult left lateral lobe liver transplantation (SALT)
- Volunteers
- 40 people
- Sponsor
- RenJi Hospital
Cirrhosis of the Liver
Trial of Faecal Microbiota Transplantation in Cirrhosis
Patients with advanced cirrhosis have enteric dysbiosis with small bowel bacterial overgrowth and translocation of bacteria and their products across the gut epithelial barrier.
- Trial name
- PROFIT (NCT02862249)
- Testing
- Faecal microbiota transplantation
- Where
- United Kingdom
- Volunteers
- 32 people
- Sponsor
- King's College London
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.